News
EPRX
6.60
+2.96%
0.19
Oppenheimer Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17
Benzinga · 1d ago
EUPRAXIA PHARMACEUTICALS INC <EPRX.O>: OPPENHEIMER INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $17
Reuters · 1d ago
Oppenheimer starts Eupraxia at Outperform, sees upside from EoE
TipRanks · 2d ago
Eupraxia Pharmaceuticals initiated with an Outperform at Oppenheimer
TipRanks · 2d ago
Cantor Fitzgerald Reaffirms Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
TipRanks · 2d ago
Eupraxia Pharmaceuticals Shareholders Back Board Slate and Auditor at June 18 AGM
TipRanks · 5d ago
Weekly Report: what happened at EPRX last week (0615-0619)?
Weekly Report · 6d ago
Eupraxia Pharmaceuticals holds annual shareholder meeting
PUBT · 06/19 20:03
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
Barchart · 06/19 15:02
Weekly Report: what happened at EPRX last week (0608-0612)?
Weekly Report · 06/15 09:42
Weekly Report: what happened at EPRX last week (0601-0605)?
Weekly Report · 06/08 09:40
Weekly Report: what happened at EPRX last week (0525-0529)?
Weekly Report · 06/01 09:42
Eupraxia Pharmaceuticals Sets June 18, 2026 Virtual AGM and Files May Form 6-K
TipRanks · 05/29 18:47
Eupraxia Pharmaceuticals Confirms Mailing of 2026 Proxy Materials to Shareholders
TipRanks · 05/29 18:27
Eupraxia Pharmaceuticals announces annual shareholder meeting
PUBT · 05/29 18:19
Eupraxia Pharmaceuticals to Showcase Pipeline at Jefferies Global Healthcare Conference
TipRanks · 05/28 21:38
VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 05/26 12:06
Why JOYY Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Benzinga · 05/26 10:00
Weekly Report: what happened at EPRX last week (0518-0522)?
Weekly Report · 05/25 09:44
Stifel Initiates Coverage of Eupraxia Pharmaceuticals (EPRX) with Buy Recommendation
NASDAQ · 05/22 00:02
More
Webull provides a variety of real-time EPRX stock news. You can receive the latest news about Eupraxia Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.